Noxopharm (ASX:NOX) Scaled Net Operating Assets : 0.14 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Noxopharm's operating assets for the quarter that ended in Dec. 2023 was A$2.00 Mil. Noxopharm's operating liabilities for the quarter that ended in Dec. 2023 was A$0.58 Mil. Noxopharm's Total Assets for the quarter that ended in Jun. 2023 was A$10.13 Mil. Therefore, Noxopharm's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.14.

Noxopharm Scaled Net Operating Assets Historical Data

The historical data trend for Noxopharm's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Scaled Net Operating Assets Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.03

2.51

0.71

0.22

0.23

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial										0.36	0.29	0.29	0.28	0.14

Competitive Comparison of Noxopharm's Scaled Net Operating Assets

For the Biotechnology subindustry, Noxopharm's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noxopharm's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noxopharm's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Noxopharm's Scaled Net Operating Assets falls into.

Noxopharm Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Noxopharm's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(7.119	-	1.055)	/	26.594
=	0.23

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	10.128	-	3.009
=	7.119

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.055	-	0	-	0
=	1.055

Noxopharm's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(1.996	-	0.581)	/	10.128
=	0.14

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	7.156	-	5.16
=	1.996

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.581	-	0	-	0
=	0.581

Noxopharm Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Noxopharm's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines